• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
PVP-K30-----pharma excipients(CAS No.9003-39-8)
Tobramycin
Povidone iodine 20% powder
Povidone iodine 10% powder
SULBACTAM SODIUM STERILE
Food Additives Bulk Sucralose Neotame Advantame Powder

Jawed Zia joins Abbott as VP, Established Pharmaceuticals, India

financialexpressJune 01, 2018

Tag: Jawed Zia , VP , Established Pharmaceuticals

Abbott has appointed Jawed Zia as VP, Established Pharmaceuticals, India. Reportedly, in this role, Zia will lead Abbott’s India pharma business. He will be responsible for Abbott’s continued growth and leadership in the country.

Zia joins Abbott from Novartis where he was the Pharma Division Head of Novartis Pharmaceuticals and Country President. Over the last 25 years of his career, Zia has been in various leadership roles with Novartis, working in its pharma and ophthalmic businesses, as well as being part of many integration projects. He has had the opportunity to work in several countries including Singapore, Turkey and Saudi Arabia.

Register as Visitor to CPhI China 2018!

Previous:Serum Institute of India and Intravacc to develop Bioneedles

Next:Sanofi Genzyme partners with MSSI to support multiple sclerosis community

Related News

InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 for Acute Myeloid Leukemia in China

PharmaSourcesSeptember 19, 2024

InnoCare Pharma announced today the approval of the Investigational New Drug (IND) to conduct the clinical trial of B-cell lymphoma-2 (BCL2) inhibitor ICP-248 in combination with azacitidine for acute myeloid leukemia (AML) in China.

Cordlife Unveils Enhanced Processing and Storage Facility in Singapore; Strengthens Processes as It Resumes Collection of Cord Blood Units in a Controlled Manner

PharmaSourcesSeptember 18, 2024

Latest Data of InnoCare’s Orelabrutinib Presented at the European Society for Medical Oncology (ESMO) Congress 2024

PharmaSourcesSeptember 14, 2024

Jawed Zia joins Abbott as VP, Established Pharmaceuticals, India | Pharmasources.com

Currax Pharmaceuticals: CONTRAVE®/MYSIMBA® Demonstrates Positive Cardiovascular Safety in a Large, Real-World Evidence Study

Biotech NewswireAugust 28, 2024

Currax Pharmaceuticals LLC announced the results of a Cardiovascular Health Outcomes Analysis.The results showed there is no evidence of excess cardiovascular risk.

You may like
More>>

PVP Powder & Solution

PVP Powder & Solution
PVP K30 Kollidon

PVP K30 Kollidon
PVP K17/K30/K90

PVP K17/K30/K90
PVP-P Insoluble PVP Series: Crospovidone (PVP-P)

PVP-P Insoluble PVP Series: Crospovidone (PVP-P)
PVP K30

PVP K30
pvp k30

pvp k30
Povidone iodine PVP Iodine

Povidone iodine PVP Iodine
  PVP Iodine

  PVP Iodine
PVP К-25

PVP К-25
Styrene/PVP Copolymer (SUNLYDONE® VB) 

Styrene/PVP Copolymer (SUNLYDONE® VB) 

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service